Over 450 Total Lots Up For Auction at Three Locations - CO 05/12, PA 05/15, NY 05/20

Augmenix announces first prostate cancer patient treated with SpaceOAR hydrogel in New Zealand

Press releases may be edited for formatting or style | June 22, 2017 Rad Oncology

“KKC is dedicated to providing the best care for our patients and the introduction of SpaceOAR hydrogel for men with prostate cancer is yet another step in achieving this,” said Dr. Leanne Tyrie, Genitourinary Radiation Oncologist and Clinical Director at the Kathleen Kilgour Centre. “The significant decrease in bowel, urinary and sexual side effects following radiotherapy when SpaceOAR hydrogel is utilised, made our decision to incorporate it as part of standard of care for prostate cancer patients very easy.”

About SpaceOAR Hydrogel
Radiation therapy in the treatment of prostate cancer can cause unintended radiation injury to adjacent healthy tissue (organs at risk). This injury can lead to a range of bowel, urinary and sexual symptoms that can affect patient health and quality of life during radiotherapy, and for years afterward. SpaceOAR hydrogel is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space, SpaceOAR hydrogel reduces the radiation dose delivered to the anterior rectum.
stats
DOTmed text ad

Your Trusted Source for Sony Medical Displays, Printers & More!

Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.

stats
SpaceOAR hydrogel is approved for use in Australia and New Zealand, cleared by the U.S. Food and Drug Administration and is currently being used in the majority of leading cancer centers in the United States. It has a European Union CE mark and is licensed in Canada. See the Instructions for Use for complete information on potential risks, warnings and precautions.

About Augmenix, Inc.
Augmenix, Inc. is a privately held U.S. company based in the Boston, Massachusetts area focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. Focusing initially on protection during prostate radiation therapy, Augmenix next-generation products will address spacing and marking applications throughout the body to improve radiotherapy and interventional oncology procedure outcomes. SpaceOAR is a registered trademark of Augmenix, Inc. More information about Augmenix and the SpaceOAR hydrogel can be found at www.Augmenix.com

About the Kathleen Kilgour Centre (KKC)
KKC opened its doors in Tauranga, New Zealand in October 2014 bringing world class radiotherapy treatment, services and support to the people in the Bay of Plenty and beyond. An amazing team of Radiation Therapy specialist clinicians give cancer patients the chance of survival and fulfilling their dreams and aspirations.

You Must Be Logged In To Post A Comment